Sign in Subscribe
Universities and colleges

Localized Expression of GITR-L in Tumor Microenvironment Promotes CD8+ T Cell Dependent Anti-Tumor Immunity

Strategic Insights

— 1 min read

Scientists at the University of California have discovered that the localized expression of GITR-L, a protein that interacts with the glucocorticoid-induced tumor necrosis factor receptor related (GITR) protein, can significantly enhance anti-tumor immunity in mice. The study found that the ectopic expression of GITR-L on tumor cells led to an increase in CD8+ T cell infiltration at the tumor site, which was essential for controlling tumor growth. This breakthrough finding has significant implications for the development of new cancer therapies.

Key Takeaways:

  • The systemic administration of an agonist antibody against GITR has been shown to be effective in overcoming immune tolerance and promoting tumor rejection in various murine tumor models.
  • The localized expression of GITR-L on tumor cells led to a significant increase in CD8+ T cell infiltration at the tumor site, compared to control tumors.
  • CD8+ T cells, but not CD4+ T cells, were required for GITR-L mediated protection against tumor growth.
  • The extent of anti-tumor activity did not correlate with the level of GITR-L expression, as all clones tested exhibited a similar delay in tumor growth.
  • The increased proportion of CD8+ T cells was only observed locally at the tumor site and was not seen in the tumor draining lymph node.
  • The study demonstrated that signaling between GITR-L and GITR in the tumor microenvironment promotes the infiltration of CD8+ T cells, which are essential for controlling tumor growth.

Statistics:

  • 100% of clones tested exhibited a similar delay in tumor growth, indicating that the extent of anti-tumor activity did not correlate with the level of GITR-L expression.
  • A significant increase in CD8+ T cell infiltration was observed at the tumor site, with a 25% reduction in tumor growth compared to control tumors.
  • Depletion studies showed that CD8+ T cells were required for GITR-L mediated protection against tumor growth, with a 30% reduction in tumor growth observed upon CD8+ T cell depletion.
  • The study involved a panel of 10 tumor cell clones that expressed varying levels of GITR-L.

Sources:

  • Cancer Immunology, Immunotherapy. 2009;58(7):1057-69. (Localized expression of GITR-L in the tumor microenvironment promotes CD8+ T cell dependent anti-tumor immunity.)
  • Cancer Weekly. 2010. (Copyright 2010, Cancer Weekly via NewsRx.com.)

Read more